HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with ...
They compared the safety profile of INCS on 45 patients in each group - Mometasone Furoate {(MF),200 micrograms once daily}, Fluticasone Furoate {(FF), 110 micrograms once daily}, and Fluticasone ...
Mometasone furoate was the most commonly prescribed (34.6%), followed by clobetasol propionate (26.7%). Ointments (53%) followed by creams (40.6%) were the most common formulations of topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback